Skip to main content
OpenTrials

Clinical trial condition

Multiple Sclerosis, Relapsing-Remitting

Explore clinical trials studying Multiple Sclerosis, Relapsing-Remitting. Study availability and eligibility vary by location and protocol.

167 public trials 17 recruiting studies
Refine in advanced search Browse all conditions

Multiple Sclerosis, Relapsing-Remitting trial results

Completed

Natalizumab Re-Initiation of Dosing

NCT00306592

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • Research Site Birmingham, Alabama, United States
  • Research Site Phoenix, Arizona, United States
  • Research Site Scottsdale, Arizona, United States
  • Research Site Little Rock, Arkansas, United States
View all 63 locations
View Trial Details
Completed

Rebif® Rebidose® Versus Rebiject II® Ease-of-Use

NCT02019550

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • Research site Cullman, Alabama, United States
  • Research Site Tuscon, Arizona, United States
  • Research Site Newport Beach, California, United States
  • Research site Fort Collins, Colorado, United States
View all 21 locations
View Trial Details
Completed

Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis

NCT00027300

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • Mayo Clinic Scottsdale Scottsdale, Arizona, United States
  • East Bay Region Associates in Neurology Berkeley, California, United States
  • UC Davis School of Medicine, Department of Neurology Davis, California, United States
  • Yale University School of Medicine, Department of Neurology New Haven, Connecticut, United States
View all 53 locations
View Trial Details
Completed

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis

NCT01116427

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • St. Josephs Hospital and Medical Center - Barrow Neurology Phonix, Arizona, United States
  • Jordan Research and Education Institute (REDI): Alta Bates Summit Medical Center Berkeley, California, United States
  • University of Southern California - Keck School of Medicine Los Angeles, California, United States
  • Newport Beach Clinical Research Associates, Inc. Newport Beach, California, United States
View all 21 locations
View Trial Details
Completed

Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis

NCT01772199

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • GSK Investigational Site Sofia, Bulgaria
  • GSK Investigational Site Sofia, Bulgaria
  • GSK Investigational Site Sofia, Bulgaria
  • GSK Investigational Site Calgary, Alberta, Canada
View all 43 locations
View Trial Details
Completed

Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis

NCT00220779

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • Barrow Neurological Institute at St. Joseph's Hospital and Medical Center Phoenix, Arizona, United States
  • Northwest NeuroSpecialists, PLLC Tucson, Arizona, United States
  • The Mt. Sinai Medical Center, Department of Neurology New York, United States
  • SUNY Health Science Center at Stony Brook, Department of Neurology Stony Brook, New York, United States
View all 37 locations
View Trial Details

Related conditions